The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1543
Secnidazole (Solosec) for Bacterial Vaginosis
The full article is available to subscribers Subscriber Login   

The FDA has approved secnidazole oral granules (Solosec – Symbiomix/Lupin) for single-dose treatment of bacterial vaginosis (BV) in adult women.

THE NEW DRUG — Secnidazole is a nitroimidazole antimicrobial with a longer half-life than metronidazole (17 vs 8 hours). It has been available for decades in many other countries for treatment of BV, trichomoniasis, and other infections.1

 

BACTERIAL VAGINOSIS — In patients with BV, hydrogen peroxide-producing lactobacilli in vaginal flora are replaced by an overgrowth of other bacteria, including anaerobes such as Gardnerella vaginalis, which leads to production of malodorous amines and an increase in vaginal secretions. Patients with BV are often asymptomatic, but vaginal discharge and/or a fishy vaginal odor can occur. In the US, the prevalence of BV is 29% among all women ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Secnidazole (Solosec) for Bacterial Vaginosis
Article code: 1543b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian